LIVIVO - Search results -

Search results

Result 1 - 10 of total 43

Search options

Article ; Online: COVID-19 fatality rates in hospitalized patients: A new systematic review and meta-analysis.

Baptista, Alexandre / Vieira, Ana M / Capela, Eunice / Julião, Pedro / Macedo, Ana

2023 Volume 16, Issue 10, Page(s) 1606–1612

Abstract: ... meta-analysis, with a total of 114609 patients. The mortality rate of COVID-19 general patients admitted ... of those patients, consulting PUBMED (The US National Library of Medicine) and EMBASE (Medical database ... patients was 16%, with quite different rates according to the different geographic areas analysed. ...

Abstract	Background: SARS-COV2 or COVID-19 disease is an infectious illness that emerged for the first time at the end of 2019, in Wuhan, China and rapidly turned out to be an international pandemic with deleterious effects all over the world. In March 2021, A. Macedo et al., has published the first meta-analysis of hospital mortality, so the authors decided to update those data at a time of emergence of new therapies and increasing vaccination rates. Methods: As the outcome of interest was the mortality in hospitalized general patients, the authors looked for articles evaluating the clinical characteristics of those patients, consulting PUBMED (The US National Library of Medicine) and EMBASE (Medical database) in an independent selection using predefined terms of search. A meta-analysis random-effect model was estimated using Mantel-Haenszel method. Heterogeneity among studies was tested using Tau Results: In a first instance 25 articles were included for final analysis with a total of 103,840 patients, but as the goal was to update the anterior data, these studies were analysed together with the 21 studies of the previous meta-analysis, with a total of 114609 patients. The mortality rate of COVID-19 general patients admitted to the hospital was 16% (95% CI 12; 21, I Conclusion: Global hospital mortality of COVID-19 of general patients was 16%, with quite different rates according to the different geographic areas analysed.
MeSH term(s)	United States ; Humans ; COVID-19 ; SARS-CoV-2 ; RNA, Viral ; Hospitalization ; Pandemics
Chemical Substances	RNA, Viral
Language	English
Publishing date	2023-07-20
Publishing country	England
Document type	Meta-Analysis ; Systematic Review ; Journal Article ; Review
ZDB-ID	2467587-8
ISSN	1876-035X ; 1876-0341
ISSN (online)	1876-035X
ISSN	1876-0341
DOI	10.1016/j.jiph.2023.07.006
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis.

Macedo, Ana / Gonçalves, Nilza / Febra, Cláudia

Annals of epidemiology

2021 Volume 57, Page(s) 14–21

Abstract: ... and EMBASE databases for articles evaluating the clinical characteristics of COVID-19 patients ... I: Conclusion: High COVID-19 mortality among general admitted patients and critical care cases should guide ... patients with COVID-19 diagnosis. The mortality rate of the COVID-19 patients was 17.1% (95% CI 12.7; 22.7 ...

Abstract	Background: Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Although general and local public health report deathly cases, case fatality rates are still largely unknown. Thus, we sought to evaluate the mortality of COVID-19. Methods: We searched PubMed and EMBASE databases for articles evaluating the clinical characteristics of COVID-19 patients that included clinical outcomes, between December 2020 and 24 April 2020. Two authors performed an independent selection using predefined terms of search. Results: We retrieved 33 studies with a total of 13,398 patients with COVID-19 diagnosis. The mortality rate of the COVID-19 patients was 17.1% (95% CI 12.7; 22.7, I Conclusion: High COVID-19 mortality among general admitted patients and critical care cases should guide resources allocations and economic burden calculations during the pandemics.
MeSH term(s)	COVID-19/mortality ; Hospital Mortality ; Humans ; Thailand
Language	English
Publishing date	2021-03-02
Publishing country	United States
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	1074355-8
ISSN	1873-2585 ; 1047-2797
ISSN (online)	1873-2585
ISSN	1047-2797
DOI	10.1016/j.annepidem.2021.02.012
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3225: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: The global case fatality rate due to COVID-19 in hospitalized elderly patients by sex, year, gross domestic product, and continent: A systematic review, meta-analysis, and meta-regression.

Esmaeili, Elham Davtalab / Azizi, Hosein / Sarbazi, Ehsan / Khodamoradi, Farzad

New microbes and new infections

2023 Volume 51, Page(s) 101079

Abstract: ... Fatality Rate (CFR) in hospitalized elderly patients is poorly investigated. This meta-analysis and meta ... pooled CFR measures for hospitalized elderly patients with COVID-19. Although COVID-19 fatality has ... included 5683 confirmed hospitalized elderly COVID-19 patients, 1809 deaths, and 19 original articles ...

Abstract	Background: Although elderly people are at a huge risk of mortality due to COVID-19, the Case Fatality Rate (CFR) in hospitalized elderly patients is poorly investigated. This meta-analysis and meta-regression aimed to generate pooled CFR due to COVID-19 in hospitalized elderly patients by sex, Gross Domestic Product (GDP), year, and continent and also to explain the potential source of the heterogeneity and variations in the pooled estimation of COVID-19 CFR. Methods: We systematically searched PubMed, Scopus, Web of Science, CINAHL, and Embase up to 31 July 2022. Eligibility assessment of records was performed independently in a blinded, standardized way by two reviewers. Meta-analysis and Meta-regression analysis were carried out to estimate pooled CFR and the potential sources of the heterogeneity. Results: The study included 5683 confirmed hospitalized elderly COVID-19 patients, 1809 deaths, and 19 original articles from 10 countries. The pooled estimate of the overall CFR, and by male and female sexes were 29%, 34%, and 24%, respectively. We found CFR was decreased by increasing female sex proportion, GDP, and year of publication. Multivariate meta-regression analysis indicated that the age and sex of patients, continent, GDP, and year of the publication together explained the majority of the heterogeneity and variations in the pooled estimate of the hospitalized elderly COVID-19 CFR. Conclusions: This review provided reliable pooled CFR measures for hospitalized elderly patients with COVID-19. Although COVID-19 fatality has decreased in hospitalized elderly patients over time, it is still high in hospitalized elderly patients and needs advanced treatment support.
Language	English
Publishing date	2023-01-04
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2750179-6
ISSN	2052-2975
ISSN	2052-2975
DOI	10.1016/j.nmni.2022.101079
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Systematic review and meta-analysis of Tuberculosis and COVID-19 Co-infection: Prevalence, fatality, and treatment considerations.

Wang, Quan / Cao, Yanmin / Liu, Xinyu / Fu, Yaqun / Zhang, Jiawei / Zhang, Yeqing / Zhang, Lanyue / Wei, Xiaolin / Yang, Li

PLoS neglected tropical diseases

2024 Volume 18, Issue 5, Page(s) e0012136

Abstract: ... review aimed to investigate the prevalence, fatality rates, and treatment outcomes of TB-COVID ... of included studies, and meta-analysis estimated co-infection fatality rates and relative risk.: Results ... compared to single COVID-19 cases. The pooled fatality rate among co-infected patients was 7.1% (95%CI: 4.0 ...

Abstract	Background: Tuberculosis (TB) and COVID-19 co-infection poses a significant global health challenge with increased fatality rates and adverse outcomes. However, the existing evidence on the epidemiology and treatment of TB-COVID co-infection remains limited. Methods: This updated systematic review aimed to investigate the prevalence, fatality rates, and treatment outcomes of TB-COVID co-infection. A comprehensive search across six electronic databases spanning November 1, 2019, to January 24, 2023, was conducted. The Joanna Briggs Institute Critical Appraisal Checklist assessed risk of bias of included studies, and meta-analysis estimated co-infection fatality rates and relative risk. Results: From 5,095 studies screened, 17 were included. TB-COVID co-infection prevalence was reported in 38 countries or regions, spanning both high and low TB prevalence areas. Prevalence estimates were approximately 0.06% in West Cape Province, South Africa, and 0.02% in California, USA. Treatment approaches for TB-COVID co-infection displayed minimal evolution since 2021. Converging findings from diverse studies underscored increased hospitalization risks, extended recovery periods, and accelerated mortality compared to single COVID-19 cases. The pooled fatality rate among co-infected patients was 7.1% (95%CI: 4.0% ~ 10.8%), slightly lower than previous estimates. In-hospital co-infected patients faced a mean fatality rate of 11.4% (95%CI: 5.6% ~ 18.8%). The pooled relative risk of in-hospital fatality was 0.8 (95% CI, 0.18-3.68) for TB-COVID patients versus single COVID patients. Conclusion: TB-COVID co-infection is increasingly prevalent worldwide, with fatality rates gradually declining but remaining higher than COVID-19 alone. This underscores the urgency of continued research to understand and address the challenges posed by TB-COVID co-infection.
MeSH term(s)	Humans ; COVID-19/mortality ; COVID-19/epidemiology ; COVID-19/complications ; Coinfection/epidemiology ; Coinfection/mortality ; Tuberculosis/mortality ; Tuberculosis/epidemiology ; Tuberculosis/complications ; Prevalence ; SARS-CoV-2
Language	English
Publishing date	2024-05-13
Publishing country	United States
Document type	Journal Article ; Systematic Review ; Meta-Analysis ; Research Support, Non-U.S. Gov't
ZDB-ID	2429704-5
ISSN	1935-2735 ; 1935-2735
ISSN (online)	1935-2735
ISSN	1935-2735
DOI	10.1371/journal.pntd.0012136
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A systematic review and meta-analysis of investigating the mutual impact of COVID-19 and psoriasis: Focusing on COVID-19 course in psoriasis and the opinion on biologics in this setting.

Ghoreishi Amin, Nazila / Khosravi, Sepehr / Atefi, Najmolsadat / Seirafianpour, Farnoosh / Farhoodi, Sahand / Goodarzi, Azadeh

Immunity, inflammation and disease

2023 Volume 11, Issue 11, Page(s) e1063

Abstract: ... odds ratios of COVID-19 infection and hospitalization rate in psoriasis patients were extracted and analyzed ... Introduction: This systematic review and meta-analysis aims to investigate the mutual impact ... to the general population. The hospitalization rate, ICU admission rate, and case fatality rate for psoriasis patients ...

Abstract	Introduction: This systematic review and meta-analysis aims to investigate the mutual impact of COVID-19 and psoriasis to inform clinical practice and future research. Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis protocol for systematic reviews and searched PubMed, Web of Science, Scopus, and Google Scholar until May 1, 2022. Eligibility criteria included full-text articles in English reporting COVID-19 treatment outcomes in psoriasis patients. Studies on animals, letters to editors, non-English studies, and studies with no access to full articles were excluded. Search results were screened and data were extracted by two groups of reviewers with any discrepancies resolved by the senior author. The risk of bias was assessed using ROBINS-I for nonrandomized studies. The hospitalization rate, Intensive Care Unit (ICU) admission rate, case fatality rate, odds ratios of COVID-19 infection and hospitalization rate in psoriasis patients were extracted and analyzed using random effects analysis to calculate pooled prevalence and odds ratios, as well as to explore heterogeneity. Results: We found 1980 records from four databases and included 20 studies after screening and removing duplicates. These studies evaluated 185,000 psoriasis patients and included eight retrospective cohort studies, one case-control study, three cross-sectional studies, and eight case series studies. The impact of the COVID-19 pandemic on psoriasis treatment and the outcome of COVID-19 infection in psoriasis patients receiving different forms of treatment were evaluated. The pooled data from included studies showed that the incidence rate of COVID-19 infection among psoriasis patients was 0.03% (confidence interval [CI]: 0.01-0.06), with a pooled odds ratio of 1.97 (CI: 0.69-5.60) compared to the general population. The hospitalization rate, ICU admission rate, and case fatality rate for psoriasis patients with COVID-19 were 0.17 (CI: 0.10-0.31), 0.06 (CI: 0.06-0.46), and 0.02 (CI: 0.01-0.04), respectively. Additionally, psoriasis patients receiving systemic nonbiologic therapy had a pooled odds ratio of 2.32 (CI: 1.18-4.57) for hospitalization compared to those using biologic agents. Conclusion: Studies have shown that biologic therapy for psoriasis did not increase the risk of hospitalization due to COVID-19 infection and may have even offered some protection. Treatment adherence was higher in psoriasis patients receiving biologic therapies than those receiving conventional therapies. These findings suggest that psoriasis treatment did not negatively impact COVID-19 infection and that treatment could be continued on a case-by-case basis during the pandemic.
MeSH term(s)	Humans ; Biological Factors/therapeutic use ; Biological Products/therapeutic use ; Case-Control Studies ; COVID-19/epidemiology ; COVID-19 Drug Treatment ; Cross-Sectional Studies ; Pandemics ; Psoriasis/drug therapy ; Psoriasis/epidemiology ; Retrospective Studies ; Systematic Reviews as Topic
Chemical Substances	Biological Factors ; Biological Products
Language	English
Publishing date	2023-11-29
Publishing country	England
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	2740382-8
ISSN	2050-4527 ; 2050-4527
ISSN (online)	2050-4527
ISSN	2050-4527
DOI	10.1002/iid3.1063
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Association of Pre-Infection Vitamin D status with COVID-19 severity

Ifra Eeman Ahmed / Azhar Ali / Abdullah Humayun

Journal of the Pakistan Medical Association, Vol 73, Iss

2023 Volume 8

Abstract: ... and mortality in hospitalized COVID-19 patients.(3). This study presents convincing evidence that low ... to a systematic review and meta-analysis of the ... ... that among hospitalized COVID-19 patients, pre-infection vitamin D insufficiency was linked to increased disease severity ...

Abstract	Madam, Vitamin D is a fat-soluble vitamin, well known for regulating serum calcium and phosphate levels by stimulating intestinal absorption, renal reabsorption of calcium in the distal convoluted tubule and bone calcium mobilization. As an important modulator of innate immunity, reduced vitamin D levels have been linked to the development of different autoimmune disorders and increased susceptibility to infectious diseases(1). Vitamin D pivotal role in inhibiting cytokine storm and inflammation reactions(1). It is reported that the active form of vitamin D enhances the antimicrobial effect of macrophages and monocytes(1). It is also involved in the stimulation and production of lymphocyte function and it also supports the differentiation and function of natural killer cells (1). Since December 2019, COVID-19 caused by SARS-CoV-2 has spread all over the globe causing unparalleled health, social and economic crises. Initially, an association of vitamin D status with SARS-CoV-2 infection was observed which has sparked debate over the advantages of vitamin D in preventing and treating this disease. A greater risk of COVID-19 was substantially related with low serum 25-(OH) Vitamin D levels. It also suggests that the patients with Vitamin D deficiency had poorer outcomes leading to comparatively longer stays in the Intensive Care Unit (ICU), and had a higher fatality rate. (2). There is much debate about whether infections caused the low D3 levels or whether a deficiency adversely affects the immune system. Recently, Amiel et al. discussed that among hospitalized COVID-19 patients, pre-infection vitamin D insufficiency was linked to increased disease severity and mortality in hospitalized COVID-19 patients.(3). This study presents convincing evidence that low D3 levels are a predictor rather than a side effect of infection (3). The study by Lorenz et. al. suggested that 50ng/mL of 25-(OH)D3 might potentially result in a mortality rate close to zero(4). According to a systematic review and meta-analysis of the ...
Keywords	Medicine ; R
Subject code	610
Language	English
Publishing date	2023-07-01T00:00:00Z
Publisher	Pakistan Medical Association
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Intensive Care and Organ Support Related Mortality in Patients With COVID-19: A Systematic Review and Meta-Analysis.

Chandel, Abhimanyu / Leazer, Sahar / Alcover, Karl C / Farley, Josiah / Berk, Joshua / Jayne, Christopher / Mcnutt, Ryan / Olsen, Meredith / Allard, Rhonda / Yang, Jiahong / Johnson, Caitlyn / Tripathi, Ananya / Rechtin, Maria / Leon, Mathew / Williams, Mathias / Sheth, Phorum / Messer, Kyle / Chung, Kevin K / Collen, Jacob

Critical care explorations

2023 Volume 5, Issue 3, Page(s) e0876

Abstract: To perform a systematic review and meta-analysis to generate estimates of mortality in patients ... 9%; : Conclusions: We present updated estimates of CFR for patients hospitalized and requiring ... with COVID-19 that required hospitalization, ICU admission, and organ support.: Data sources: A systematic ...

Abstract	To perform a systematic review and meta-analysis to generate estimates of mortality in patients with COVID-19 that required hospitalization, ICU admission, and organ support. Data sources: A systematic search of PubMed, Embase, and the Cochrane databases was conducted up to December 31, 2021. Study selection: Previously peer-reviewed observational studies that reported ICU, mechanical ventilation (MV), renal replacement therapy (RRT) or extracorporeal membrane oxygenation (ECMO)-related mortality among greater than or equal to 100 individual patients. Data extraction: Random-effects meta-analysis was used to generate pooled estimates of case fatality rates (CFRs) for in-hospital, ICU, MV, RRT, and ECMO-related mortality. ICU-related mortality was additionally analyzed by the study country of origin. Sensitivity analyses of CFR were assessed based on completeness of follow-up data, by year, and when only studies judged to be of high quality were included. Data synthesis: One hundred fifty-seven studies evaluating 948,309 patients were included. The CFR for in-hospital mortality, ICU mortality, MV, RRT, and ECMO were 25.9% (95% CI: 24.0-27.8%), 37.3% (95% CI: 34.6-40.1%), 51.6% (95% CI: 46.1-57.0%), 66.1% (95% CI: 59.7-72.2%), and 58.0% (95% CI: 46.9-68.9%), respectively. MV (52.7%, 95% CI: 47.5-58.0% vs 31.3%, 95% CI: 16.1-48.9%; Conclusions: We present updated estimates of CFR for patients hospitalized and requiring intensive care for the management of COVID-19. Although mortality remain high and varies considerably worldwide, we found the CFR in patients supported with MV significantly improved since 2020.
Language	English
Publishing date	2023-03-03
Publishing country	United States
Document type	Journal Article ; Review
ISSN	2639-8028
ISSN (online)	2639-8028
DOI	10.1097/CCE.0000000000000876
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The prevalence of pediatric asthma hospitalizations at different stages of the COVID-19 pandemic: A systematic review and meta-analysis study protocol.

Abdelrahim, Reem / Gao, Zhiwei / Smith, Mary Jane / Newhook, Leigh Anne

PloS one

2023 Volume 18, Issue 8, Page(s) e0289538

Abstract: ... cases and hospitalization rates.: Objectives: To investigate the impact of the COVID-19 pandemic ... governmental restrictions and viral mutants have been introduced throughout the pandemic, affecting COVID-19 ... of hospitalization in children. The COVID-19 pandemic has introduced several challenges that have impacted ...

Abstract	Background: Asthma is a highly prevalent chronic inflammatory lung disease and is a frequent cause of hospitalization in children. The COVID-19 pandemic has introduced several challenges that have impacted the delivery of care for vulnerable patients, including asthmatic children. Asthmatic children without immediate access to healthcare services can face severe and fatal consequences. Furthermore, various governmental restrictions and viral mutants have been introduced throughout the pandemic, affecting COVID-19 cases and hospitalization rates. Objectives: To investigate the impact of the COVID-19 pandemic on the prevalence of asthma hospitalizations during various stages of the pandemic. We also aim to compare asthma hospital admissions during the pandemic to pre-pandemic periods. Methods and analysis: The databases PubMed (MEDLINE), EMBASE, CINAHL, and the Cochrane library will be used to identify relevant articles between the start of the pandemic and the date of the search strategy. Studies will be included if they examine hospital admissions for pediatric (0 to 18 years) asthma patients, regardless of asthma severity, sex, ethnicity or race. Observational retrospective cohort, prospective cohort, and cross-sectional studies will be included. A meta-analysis will be conducted if there are ≥2 articles. Else, a narrative review will be used to report our results. Trial registration: PROSPERO registration number: CRD42022337606.
MeSH term(s)	Humans ; Child ; COVID-19/epidemiology ; COVID-19/complications ; Pandemics ; Prevalence ; Cross-Sectional Studies ; Prospective Studies ; Retrospective Studies ; Asthma/epidemiology ; Asthma/etiology ; Hospitalization ; Meta-Analysis as Topic ; Systematic Reviews as Topic
Language	English
Publishing date	2023-08-04
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0289538
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Congenital Bleeding Disorders and COVID-19—A Systematic Literature Review

Dorgalaleh, Akbar / Safdari, Seyed Mehrab / Tabibian, Shadi / Shams, Mahmood / Dabbagh, Ali / Rezazadeh, Azadeh

Seminars in Thrombosis and Hemostasis

(Editorial Compilation—Part XV)

2023 Volume 50, Issue 04, Page(s) 552–568

Abstract: ... to prevent COVID-19 on patients with CBDs. We performed a systematic literature review using relevant ... of 31 included studies, 12 case series covering 770 patients with CBD and COVID-19 were further analyzed ... fever (4.7%), and headache (4%). COVID-19 in patients with CBDs appears to provoke thrombotic ...

Series title	Editorial Compilation—Part XV
Abstract	Hypercoagulability is a prominent feature of coronavirus disease 2019 (COVID-19) and can lead to fatal consequences. Although the impact of COVID-19 on several disorders is well-established, its effect on congenital bleeding disorders (CBDs) is not well-documented. To address this ambiguity, a systematic review was conducted on the available studies to determine the impact of COVID-19 and vaccination aimed to prevent COVID-19 on patients with CBDs. We performed a systematic literature review using relevant keywords and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) protocol. We conducted our search on the PubMed, Scopus, and Web of Science databases until July 2023. Out of 31 included studies, 12 case series covering 770 patients with CBD and COVID-19 were further analyzed. The majority of the patients had hemophilia A ( n = 352, ∼46%) or hemophilia B ( n = 74, ∼10%), while the remaining patients had von Willebrand disease ( n = 43, 5.6%) or rare bleeding disorders (n = 27, 3.5%). A total of 25 deaths (3.2%) and 22 intensive care unit admissions (2.8%) were recorded. Bleeding complications were reported in the majority of the 12 case series ( n = 7, 58.3%) and in most of the case reports ( n = 8, ∼57%), while thrombotic complications were only reported in two studies (16.6%). The mortality rate ranged from 0% in five studies (41.6%) to 5.7% and the rate of hospitalization ranged from 0 to 40%. Bleeding complications were reported in a range of 0 to 81%, while the thrombotic complication rate in one study was 6.9%. The mortality rate varied from 0 to 5.7%, and the hospitalization rate ranged from 0 to 40%. Bleeding complications were reported in a range of 0 to 81%, while the rate of thrombotic complications in one study was 6.9%. Vaccination was reported in five case series, which included 821 patients with CBDs with the majority having hemophilia A ( n = 479; 67.2%) and hemophilia B ( n = 85; ∼12%). The most frequently reported side effects were myalgia (6.5%), flu-like symptoms (4.8%), fever (4.7%), and headache (4%). COVID-19 in patients with CBDs appears to provoke thrombotic complications and bleeding events more frequently, as well as a higher rate of hospitalization, which may be partially due to the increased risk of bleeding events. Although it seems that patients with CBD have lower mortality rates, further studies are necessary to fully understand this, especially considering comorbidities and low number of available studies.
Keywords	congenital bleeding disorders ; COVID-19 ; SARS-CoV-2 ; thrombosis ; bleeding ; mortality
Language	English
Publishing date	2023-09-27
Publisher	Thieme Medical Publishers, Inc.
Publishing place	Stuttgart ; New York
Document type	Article
ZDB-ID	196901-8
ISSN	1098-9064 ; 0094-6176
ISSN (online)	1098-9064
ISSN	0094-6176
DOI	10.1055/s-0043-1775733
Database	Thieme publisher's database

In stock of ZB MED Cologne/Königswinter

Zs.A 1259: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Prevalence and risk of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis.

Wang, Feier / Ma, Yubo / Xu, Shanshan / Liu, Huanhuan / Chen, Yuting / Yang, Hui / Shao, Ming / Xu, Wei / Kong, Jiangping / Chen, Liwen / Xu, Shengqian / Shuai, Zongwen / Pan, Faming

Clinical rheumatology

2022 Volume 41, Issue 7, Page(s) 2213–2223

Abstract: ... for many years. This meta-analysis aims to assess the risk of COVID-19 in patients with rheumatic diseases ... of COVID-19 in patients with rheumatic diseases has been discussed in previous meta-analysis ... disease-modifying antirheumatic drugs did not affect the hospitalization rate and mortality in rheumatism patients with COVID-19. ...

Abstract	Objectives: COVID-19 pandemic has already had a tremendous impact on the process of human society; the survival of mankind and the healthy living environment deterioration with the influence will last for many years. This meta-analysis aims to assess the risk of COVID-19 in patients with rheumatic diseases. Methods: PubMed, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Chinese Biomedical Database (CBM) were systematically searched with no language restriction up to July 5, 2021. The pooled rates were synthesized by fixed effect model or random effect model depending on heterogeneity. Results: A total of 83 articles were included in this meta-analysis. The incidence of COVID-19 in patient with rheumatic diseases was 0.0190 (95% CI: 0.0136-0.0252), and the hospitalization rate, intensive care unit admission rate, mechanical ventilation rate, and case fatality rate of patients with rheumatic diseases infected with COVID-19 were 0.4396 (95% CI: 0.3899-0.4898), 0.0635 (95% CI: 0.0453-0.0836), 0.0461 (95% CI: 0.0330-0.0609), and 0.0346 (95% CI: 0.0218-0.0493), respectively. Conclusions: Our research shows that patients with rheumatic diseases have great risk of COVID-19. Differences in COVID-19 incidence, hospitalization rates, and mortality rates in regions were statistically significant. We still need to pay attention to the risk of COVID-19 in patients with rheumatic diseases. Key points: • Although the risk of COVID-19 in patients with rheumatic diseases has been discussed in previous meta-analysis, their research directions were inconsistent, and few studies focus on prevalence or serious outcomes of COVID-19 in patient with rheumatic diseases, while the quality of these articles was variable. • The incidence of COVID-19 and serious clinical outcomes in patients with rheumatic diseases were still high along with differential risks in most regions. • The use of glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs did not affect the hospitalization rate and mortality in rheumatism patients with COVID-19.
MeSH term(s)	COVID-19/epidemiology ; Humans ; Pandemics ; Prevalence ; Rheumatic Diseases/complications ; Rheumatic Diseases/epidemiology ; SARS-CoV-2
Language	English
Publishing date	2022-03-30
Publishing country	Germany
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	604755-5
ISSN	1434-9949 ; 0770-3198
ISSN (online)	1434-9949
ISSN	0770-3198
DOI	10.1007/s10067-022-06087-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1740: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito